Alumis Inc. (ALMS) Stock AnalysisALMSAlumis Inc.

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alumis Inc is currently not a strong buy. The current price is $6.12, with an RSI of 27.106 indicating oversold conditions. However, the stock has seen a significant decline of 14.53% over the last five days and a year-to-date change of -31.66%. While there are positive catalysts like the upcoming FDA application for psoriasis, the recent trial failures pose a major risk, with analysts downgrading their price targets significantly, such as Oppenheimer from $55 to $37.